Francis deSouza resigns as Illumina boss after proxy battle with Carl Icahn

Illumina chief government Francis deSouza has resigned following a bruising proxy battle with activist investor Carl Icahn over the way forward for the world’s largest gene sequencing firm.

Illumina mentioned on Sunday that the corporate’s board of administrators had accepted deSouza’s fast resignation and begun a seek for a substitute. DeSouza will keep on in an advisory capability at Illumina till July 31, mentioned the corporate.

Illumina mentioned Charles Dadswell, a senior vice-president and basic counsel on the firm, has been named interim chief government.

The resignation of deSouza, who was appointed chief government in 2016, follows the departure final month of Illumina chair John Thompson, who was ousted in a shareholder vote following a proxy marketing campaign by Icahn.

The 87-year-old activist investor led a shareholder marketing campaign that centered on Illumina’s “reckless resolution” to shut its $8bn acquisition of most cancers take a look at developer Grail in 2021 towards the desires of EU and US antitrust regulators.

Icahn, who has a 1.4 per cent stake in Illumina, mentioned it was “inexplicable and unforgivable” that the board led by Thompson went forward with the deal with out ascertaining whether or not it might get clearance from EU regulators.

Icahn had known as on Illumina’s board to fireside deSouza, saying he had masterminded a “Hail Mary” powergrab by buying Grail and permitting the core enterprise to deteriorate. He additionally alleged most of Illumina’s administrators had been handpicked by deSouza — a declare the corporate denied.

DeSouza survived the management vote on Could 25, receiving 71 per cent help from shareholders. However the proxy battle weakened his place, and he started negotiations with the corporate final week on his exit, in accordance with sources with information of the talks.

Illumina mentioned there isn’t any severance cost related to the resignation.

The Grail acquisition has plunged Illumina into years-long authorized battles with antitrust regulators in Brussels and Washington at a time when its core enterprise is below stress from new entrants to gene sequencing.

In December, Brussels ordered Illumina to divest Grail and is planning to difficulty a nice value as much as $453mn for “gun leaping”.

The US Federal Commerce Fee has additionally ordered Illumina to divest Grail. Illumina is interesting towards the EU and US regulators’ orders. Icahn additionally alleged the board lacked independence and that the majority administrators had been handpicked by deSouza.

Illumina’s market capitalisation has plunged from $75bn in August 2021, when it purchased Grail, to lower than $32bn as of Friday.

In a letter to Illumina staff posted to LinkedIn, deSouza mentioned his resolution to depart was “extraordinarily troublesome” however he felt a way of “fulfilment and satisfaction at the place we’ve taken the corporate”, together with the acquisition of Grail.

“My perception within the potential of Grail’s doubtlessly life-saving know-how and the advantages of merging it with Illumina stays unshakeable,” he wrote.

However many shareholders are sceptical about Illumina’s willpower to carry on to Grail and need the board to barter a take care of EU authorities to spin off the most cancers diagnostics firm.

The departure of deSouza, who can be a director of Disney, comes at a crucial time for Illumina, which lately launched a brand new era of gene sequencing machines, known as NovaSeq X.

The corporate faces rising competitors from a number of new entrants and Chinese language gene sequencing firm MGI.

Back To Top